Use of guanfacine in the treatment of behavioral disorders
US5854290A · kind A · utility
32Cited by
1References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 21, 1995 |
| Grant date | Dec 29, 1998 |
| Priority date | — |
| Expiry date | Sep 21, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/165
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.